Navigation Links
MEDomics Announces MitoDx(TM), the First NextGen Mitochondrial Genome Diagnostic Test
Date:6/9/2009

Highly Sensitive Genetic Test Provides Early Diagnosis of Mitochondrial Diseases

LOS ANGELES, June 9 /PRNewswire/ -- MEDomics, LLC (www.medomics.com) announces an innovative test for early diagnosis of mitochondrial diseases, a group of disorders that can result in neurological dysfunction, muscle weakness, gastrointestinal symptoms, migraine headaches, blindness, deafness, and diabetes. The MEDomics mitochondrial genome test, MitoDx(TM), uses the revolutionary NextGen sequencing technology to detect all mutations in any of the 37 mitochondrial DNA genes. The MEDomics team of experts provides interpretation of the functional significance of detected mutations. This comprehensive test offers exceptionally high diagnostic utility for suspected mitochondrial disease, enabling potentially lifesaving therapy and accurate risk counseling.

Disease from mutations in mitochondrial DNA is now thought to be common in both adults and children. In childhood, mitochondrial disease is more common than muscular dystrophy or cancer. Most mitochondrial disease may go undiagnosed because a primary care physician does not suspect the disease or because the causative mutation is missed by current methods.

"To my knowledge, MEDomics is the first laboratory to offer a whole genome clinical diagnostic test utilizing the powerful NextGen sequencing technique," says Steve S Sommer, MD, PhD, Founder and President of MEDomics.

Mitochondria are the "power plants" of the cell, providing energy for cellular processes, including growth, and metabolism. Mutations in mitochondrial genes may decrease energy production and affect multiple organs. Since cells contain hundreds of mitochondrial DNA molecules, any particular tissue may contain mitochondrial DNA molecules that are all identical, or there may be a fraction that differs. When both normal and mutant molecules exist, the mitochondria are said to be "heteroplasmic." The heteroplasmic fraction of mutations can differ substantially among tissues.

It is critical to detect heteroplasmy sensitively, since even low levels in blood, which is routinely tested, may reveal disease affecting other organs. Such low levels of heteroplasmy in blood are generally not detected by standard methods, but are detected by the MEDomics test utilizing NextGen sequencing technology. The error rate determines how small a mutant fraction is reliably detected. MEDomics uses the Applied Biosystems SOLiD(TM) 3 NextGen sequencing platform which has an exceptionally low error rate, allowing detection of heteroplasmy down to about 1%.

The MEDomics NextGen mitochondrial genome test can help diagnose mitochondrial disease, enabling life-saving therapy decisions and allowing for accurate family risk counseling.

About MEDomics

MEDomics is a molecular diagnostic laboratory founded in 2008 by Steve S. Sommer, MD, PhD, with the mission of providing Mutation Expert-based Diagnosis ("MED") to support the physician in delivering personalized medicine based on analysis of the patient's genome ("omics"). The mutation experts at MEDomics provide unparalleled quality interpretation to aid the practicing physician.

Dr. Sommer is a Founding Fellow of the American College of Medical Genetics with 25 years experience in Clinical Molecular Diagnosis and over 300 scientific publications and patents. During the past few years, his personalized cancer genetics research and clinical team, including Kelly Gonzalez, MS, and Bill Scaringe, MS, discovered mutation showers. Mutation showers may occasionally cause cancer in an instant. His neuropsychiatric genetics team, including Carolyn Buzin, PhD, also helped to define the first genes for which mutations strongly predispose to schizophrenia or autism. Carolyn Buzin, Kelly Gonzalez, and Bill Scaringe are currently Senior Scientist, Director of Genetic Counseling & Education, and Director of Bioinformatics at MEDomics, respectively.

Richard Boles, MD, Director of the Mitochondrial and Metabolic Disorders Clinic at Childrens Hospital, Los Angeles, is the distinguished clinical consultant for MEDomics in mitochondrial diseases.


'/>"/>
SOURCE MEDomics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University
2. ADVENTRX Pharmaceuticals Announces Financing
3. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
4. Sirius Genomics Announces 2009 Board of Directors
5. Platoon Fitness Announces Platoon University
6. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
8. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
9. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
10. Pharmaxis Announces Placement of $47 Million and Share Purchase Plan
11. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):